Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Neoplasm Metastasis 2 Rheumatoid Arthritis, Systemic Juvenile 1 Periodic Fevers Syndrome 1 Mevalonate Kinase Deficiency 1 Lung Neoplasms 1 Cryopyrin-Associated Periodic Syndromes 1 Carcinoma 1 Bronchiolitis Obliterans Syndrome 1 Arthritis, Juvenile 1 Arthralgia 1

Interventions

Carboplatin 67 Cisplatin 57 Paclitaxel 42 Radiotherapy 35 Pemetrexed 34 Gemcitabine 31 Docetaxel 31 Etoposide 25 pembrolizumab 21 Vinorelbine 20 Erlotinib Hydrochloride 13 Magnetic Resonance Spectroscopy 12 Gefitinib 11 Specimen Handling 10 Radiosurgery 10 Drug Therapy 10 Bevacizumab 10 durvalumab 9 Nivolumab 9 Vinblastine 6 Topotecan 6 Surgical Procedures, Operative 6 Cyclophosphamide 6 atezolizumab 5 Standard of Care 5 Platinum 5 Immunoglobulin G 5 Ifosfamide 5 Disulfides 5 Dexamethasone 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lung Neoplasms × canakinumab × Clear all

NCT05725343 2023-02-13

CANAL

Mario Negri Institute for Pharmacological Research

Phase 3 Terminated

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡